ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $454,000 | -11.7% | 14,750 | -15.7% | 0.15% | +98.6% |
| Q1 2016 | $514,000 | -90.6% | 17,487 | -85.6% | 0.07% | -86.1% |
| Q2 2015 | $5,448,000 | +723.0% | 121,085 | +460.2% | 0.53% | +718.5% |
| Q1 2015 | $662,000 | -39.8% | 21,615 | -0.0% | 0.06% | -38.1% |
| Q4 2014 | $1,099,000 | -70.4% | 21,618 | -76.9% | 0.10% | -67.3% |
| Q3 2014 | $3,711,000 | +703.2% | 93,771 | +364.9% | 0.32% | +1428.6% |
| Q3 2013 | $462,000 | +17.9% | 20,168 | -8.9% | 0.02% | +31.2% |
| Q2 2013 | $392,000 | – | 22,149 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |